GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
基本信息
- 批准号:7576916
- 负责人:
- 金额:$ 32.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-01 至 2012-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdjuvanticityAllelesAntigen PresentationAntigensAreaAutoantigensCD34 geneChemicalsChimeric ProteinsCouplingCross PresentationDataDendritic CellsEnzymesEpitopesGenerationsGenesGeneticHematopoietic stem cellsHumanImmuneImmune ToleranceImmune responseImmunityIn VitroLangerhans cellLeadLinkLymphocyteMalignant NeoplasmsMediatingMemoryMethodsModelingModificationMolecularMutationMyelogenousNatural ImmunityNatural Killer CellsPlasmid Cloning VectorPropertyProteinsPublic HealthResidual NeoplasmRestRetroviral VectorSeriesSmall Interfering RNASolutionsT-LymphocyteTestingThinkingTimeTryptophan 2,3 DioxygenaseTumor Antigensbasecancer cellcytokineimmunogenicimprovedinhibitor/antagonistinterestmelanomamethyl tryptophannovel strategiesresponsevector
项目摘要
DESCRIPTION (provided by applicant): Advances in our understanding of human dendritic cells have resolved many important unknowns about the onset of innate and adaptive immunity and how dendritic cells could control these responses against cancer. Tumor antigens are poor immunogens by themselves, because they are either self or altered-self antigens. Hence the bar to overcoming tolerance toward cancer-self antigens, while attainable, is quite high. Dendritic cells can circumvent many of these barriers by presenting tumor antigens in association with all the other requisite molecules that elicit immune reactivity. Countervailing suppressor mechanisms involving indoleamine 2,3-dioxygenase (IDO) and mediated by regulatory lymphocytes must also be addressed, however. Genetic strategies offer advantages in coupling tumor antigens to dendritic cells. Multiple epitopes can be expressed, tailored to a variety of MHC alleles. Antigen-presentation is sustained over time, cytokines and other costimulatory molecules can be manipulated, and immune suppressor mechanisms can be altered. We will address these areas in a series of testable hypotheses using human Langerhans-type dendritic cells, genetically modified by retroviral or plasmid vectors to express melanoma antigens and other proteins of interest. We will introduce IL-12p70 by genetic alteration of Langerhans cells to stimulate and harness the adjuvant properties of natural killer (NK) cells. Novel approaches will also be tested for the sustained activation of Langerhans cells and improved cross-presentation of opsonized tumor antigen through transduced expression of the activating Fc-gamma Rll, CD32a. This will be tested in combination with gene-based IL-12p70-Fc fusion constructs to assess increased cytokine adjuvanticity. Genetic methods that interfere with suppressor mechanisms involving IDO and mediated by regulatory lymphocytes will be studied. The results of these studies should lead to improved, coordinate stimulation of innate and adaptive immunity against cancer by a single, genetically optimized dendritic cell. (Relevance to public health/Lay summary: Genetic alterations of specialized Langerhans-type dendritic cells will be tested and improved to increase immunity against cancer, using melanoma as the model. These approaches should find their greatest application in treating minimal residual disease after primary therapy.)
描述(由申请人提供):我们对人类树突状细胞的理解的进展已经解决了许多关于先天性和适应性免疫的发生以及树突状细胞如何控制这些抗癌反应的重要未知因素。肿瘤抗原本身是弱免疫原,因为它们是自身抗原或改变自身的抗原。因此,克服对癌症自身抗原的耐受性的障碍虽然是可以实现的,但却相当高。树突状细胞可以通过呈递肿瘤抗原以及引发免疫反应的所有其他必需分子来绕过许多这些屏障。然而,还必须解决涉及吲哚胺2,3-双加氧酶(IDO)和调节淋巴细胞介导的抵消抑制机制。遗传策略在将肿瘤抗原偶联至树突状细胞方面提供了优势。可以表达多个表位,针对多种MHC等位基因进行定制。抗原呈递随时间持续,细胞因子和其他共刺激分子可以被操纵,并且免疫抑制机制可以被改变。我们将解决这些领域的一系列可测试的假设,使用人类朗格汉斯型树突状细胞,基因修饰的逆转录病毒或质粒载体表达黑色素瘤抗原和其他蛋白质的兴趣。我们将通过遗传改变朗格汉斯细胞来引入IL-12 p70,以刺激和利用自然杀伤(NK)细胞的佐剂特性。还将测试新方法的朗格汉斯细胞的持续活化和通过活化性Fc-γ RII、CD 32a的转导表达改善的调理肿瘤抗原的交叉呈递。这将与基于基因的IL-12 p70-Fc融合构建体组合进行测试,以评估增加的细胞因子佐剂性。遗传学方法,干扰抑制机制,涉及IDO和调节淋巴细胞介导的将进行研究。这些研究的结果应该导致通过单一的遗传优化的树突状细胞来改善、协调刺激针对癌症的先天性和适应性免疫。(与公共卫生的相关性/非专业总结:将使用黑色素瘤作为模型,测试和改进特化朗格汉斯型树突细胞的遗传改变,以提高对癌症的免疫力。这些方法应该在治疗初级治疗后的微小残留疾病中找到最大的应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James William Young其他文献
James William Young的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James William Young', 18)}}的其他基金
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC
人类树突细胞和同种异体中先天性和适应性免疫的发生
- 批准号:
7318390 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
8120855 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7415210 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7266455 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
8215911 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7765556 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma
黑色素瘤中基因修饰的自体树突状细胞疫苗的免疫反应
- 批准号:
7244117 - 财政年份:2006
- 资助金额:
$ 32.19万 - 项目类别:
Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma
黑色素瘤中基因修饰的自体树突状细胞疫苗的免疫反应
- 批准号:
7111373 - 财政年份:2006
- 资助金额:
$ 32.19万 - 项目类别:
Alemtuzumab treatment of steroid-refractory acute GvHD
阿仑单抗治疗类固醇难治性急性 GvHD
- 批准号:
6797077 - 财政年份:2004
- 资助金额:
$ 32.19万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别: